MUC1: Naked DNA Cancer Vaccine
Development Stage: 4 - In vivo Proof-of-Principle
Description
In vivo Proof-of-Principle
Mucin 1 (MUC1 or Polymorphic Epithelial Mucin, PEM) is a high MW glycoprotein expressed on the cell surface of epithelial cells. The increased expression and/or aberrant glycosylation of MUC-1 is associated with a variety of adenocarcinomas including those of breast, ovary, lung, liver, colorectal and pancreas. As a result, MUC1 has attracted considerable interest as a potential tumour antigen for development of anti-cancer vaccines. Indeed, clinical trial results (presented at ASCO 2005) have shown that vaccination with MUC1 peptide or virally delivered MUC1 DNA induces effective anti tumour responses and extends survival time in selected groups of patients.
Non-viral DNA based vaccines have great potential for treatment of cancer in both prophylactic and therapeutic settings. The ease of manufacture allied with a usually excellent toxicity profile makes DNA based vaccines clinically and commercially attractive approach for cancer vaccination.
CRT is seeking licensees for a package of patents, materials and know-how for development of non-viral DNA based vaccination against the MUC1 tumour antigen.
The commercial package available for licensing includes:
- Exclusive license to CRT’s MUC1 DNA related patent portfolio in the field of non-viral DNA immunotherapy
- Non-exclusive license to CRT’s MUC1 transgenic mouse model
- Murine cell lines expressing human MUC1 and parental control cell lines for tumour challenge experiments
For more information please contact
Dr Raj Mehta
+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)